Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, NewTrader2017
Search This Board: 
Last Post: 10/22/2017 8:23:49 AM - Followers: 121 - Board type: Free - Posts Today: 2
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:57:33 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:56:09 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:55:17 PM
INNV News: Current Report Filing (8-k) 09/27/2017 06:06:18 AM
INNV News: Current Report Filing (8-k) 08/31/2017 06:11:33 AM
#11803  Sticky Note $19B market. I think I'd be loading up BooDog 10/03/17 06:04:18 AM
#11037  Sticky Note Innovus Pharma Orders its First Commercial Batch of kkpennies 08/09/17 02:44:19 PM
#11943   Haha. So true, tf. I will miss my Batermere 10/19/17 09:35:11 PM
#11942   I know nitrous, Dr. Bat, and MJ twistedfreak 10/19/17 09:06:01 PM
#11941   Nope. I weaned myself off of it. Marijuana Batermere 10/19/17 09:04:26 PM
#11940   Man, Cubbies looking like they're going to be twistedfreak 10/19/17 09:03:35 PM
#11939   That sucks. Hope you have a home setup. You twistedfreak 10/19/17 09:00:49 PM
#11938   I retired last week. No more nitrous oxide. Sigh. Batermere 10/19/17 08:15:33 PM
#11937   Not true tf. It is material. INNV bought ShawnP123 10/19/17 08:11:38 PM
#11936   Sorry jtaylor I didn't read for second post. ShawnP123 10/19/17 08:07:51 PM
#11935   Back to your nitrous tank doc. Nothing to twistedfreak 10/19/17 07:52:18 PM
#11934   It all depends on whose non-disclosure it is. twistedfreak 10/19/17 07:49:33 PM
#11933   Hahahahaha. Now that is hilarious. And so true. Batermere 10/19/17 07:39:55 PM
#11932   You're100% Wrong. Then why the non-disclosure if it ShawnP123 10/19/17 07:36:43 PM
#11931   INNV is worthless and so am I , NewTrader2017 10/19/17 07:13:10 PM
#11930   Misunderstanding here. I was referring to the fact jtaylor68 10/19/17 06:35:59 PM
#11929   That's exactly what I think. We may never twistedfreak 10/19/17 05:58:27 PM
#11928   The application/approval/rejection has nothing to do with the jtaylor68 10/19/17 05:18:41 PM
#11927   According to Shawn, INNV must disclose to its twistedfreak 10/19/17 04:25:40 PM
#11926   Does anyone here think that the original Fluticare gi197845 10/19/17 01:33:21 PM
#11925   Q3 revs will be lower than Q1 and gi197845 10/19/17 12:26:48 PM
#11924   This 3 Q better be organsmic jbdiver 10/19/17 11:14:26 AM
#11923   I see we had another popcorn fart PR jbdiver 10/19/17 11:12:27 AM
#11922   That would be good but wouldn't be the ShawnP123 10/18/17 04:11:02 PM
#11921   Yes, he did say Q3 is historically their jtaylor68 10/18/17 03:03:12 PM
#11920   Again, you apparently don't understand that an NDA jtaylor68 10/18/17 02:56:57 PM
#11919   I think Q3 & Q4 will be the ShawnP123 10/18/17 02:51:23 PM
#11918   Cant discuss what management keeps a secret. If twistedfreak 10/18/17 02:42:07 PM
#11917   I dont give a rats ass if other twistedfreak 10/18/17 02:37:18 PM
#11916   None of that makes any sense. This is jtaylor68 10/18/17 02:35:57 PM
#11915   You seem to care a lot. It has jtaylor68 10/18/17 02:28:49 PM
#11914   Grasping at straws. Novalere was going to get twistedfreak 10/18/17 02:26:23 PM
#11913   Who cares? twistedfreak 10/18/17 02:17:38 PM
#11912   It's beyond me how anyone can interpret anything jtaylor68 10/18/17 02:11:01 PM
#11911   No, that's not quite the correct comparison. First, jtaylor68 10/18/17 02:00:27 PM
#11910   LOL. Great point. IMO, this ANDA thing is twistedfreak 10/18/17 11:19:11 AM
#11909   Jtaylor- Hmmmmm I guess someone screwed up when ShawnP123 10/18/17 01:52:22 AM
#11908   Nothing unusual at all about this non-disclosure. Lots jtaylor68 10/17/17 07:25:42 PM
#11907   Some heavy trading going on... lol smh. At jbdiver 10/17/17 11:08:27 AM
#11905   Absolutely since it is critical to the stock ShawnP123 10/17/17 09:22:56 AM
#11903   As far as I know, it was never ShawnP123 10/17/17 08:18:17 AM
#11902   Should have invested in NFLX, not this boat anchor. gi197845 10/16/17 07:18:19 PM
#11901   Hey Shawn, I'm being called out for not twistedfreak 10/16/17 06:13:02 PM
#11900   Don of the Bear Synicate! Havent seen you jbdiver 10/16/17 07:33:22 AM
#11899   I bought 500,000 last time at 5 cents, biotech2 10/15/17 10:02:03 PM
#11898   Good luck with that you will need. You must Adrock 10/15/17 09:54:49 PM
#11897   Im loving it, just keep averaging down until biotech2 10/15/17 09:53:15 PM
#11896   How’s everyone feeling about the stock price? I did Adrock 10/15/17 08:17:28 PM
#11895   You know it's a sure sign that the gi197845 10/15/17 11:51:29 AM
#11894   It would be really swell if Damaj would twistedfreak 10/14/17 06:02:20 PM
#11893   Boo, you're spot on. Zacks is f'n horrible. twistedfreak 10/14/17 05:56:26 PM
#11892   Hopefully, this will pan out for us and gi197845 10/14/17 11:59:38 AM